Table 8.

Effect of withdrawal of CsA or Pred, compared with continuation of MMF/CsA/Pred therapy, on lipid metabolism at 6, 9, and 24 mo (mean ± SD)

GroupMonth 6Month 9Month 24
a ANOVA (Kruskal-Wallis test) for comparison between groups P < 0.05
MMF/Pred
    total cholesterol (mmol/L)6.63 ± 1.816.04 ± 1.646.16 ± 1.37
    ratio total/HDL5.8 ± 2.65.3 ± 2.74.9 ± 1.7
    triglycerides (mmol/L)2.56 ± 1.982.30 ± 2.662.18 ± 1.90a
    cholesterol-lowering medication (%)0216
MMF/CsA
    total cholesterol (mmol/L)6.69 ± 1.426.1 ± 1.245.69 ± 1.22
    Ratio total/HDL6.0 ± 2.46.6 ± 2.85.7 ± 2.5
    triglycerides (mmol/L)2.59 ± 1.312.62 ± 1.392.8 ± 1.29a
    cholesterol-lowering medication (%)0518
MMF/CsA/Pred
    total cholesterol (mmol/L)6.66 ± 1.626.61 ± 1.546.19 ± 1.28
    ratio total/HDL6.0 ± 2.45.7 ± 2.25.1 ± 1.9
    triglycerides (mmol/L)2.62 ± 2.122.33 ± 1.132.23 ± 1.22
    cholesterol-lowering medication (%)6415